* Note: Prices are in Million (M) USD.
Description:
Pulse Biosciences, Inc. is a leading innovator in bioelectrical medicine, headquartered in Hayward, California, with a focus on transforming therapeutic options through its proprietary Nano-Pulse Stimulation (NPS) technology. This advanced platform offers non-invasive treatment solutions that target cellular processes, fostering healing in critical medical areas such as dermatology and oncology. With a commitment to addressing substantial unmet medical needs, Pulse Biosciences is strategically positioned for growth in the dynamic field of bioelectrical medicine, presenting a compelling investment opportunity for institutional investors looking to support breakthrough health technologies.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $95 M
Debt : $2 M
EBITDA : $-76 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Medical instruments & supplies
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 11 overlapping fiscal years (max 20).Average Free Cash Flow: $-27 M
Average Revenue: $0 M
Revenue Converted To Free Cash Flow (%): -11,495.5%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $0 M
Revenue 5 Years Ago (2019-12-31): $0 M
Total Growth over 5 Years: 0.0%
5-Year Revenue CAGR (Historical): 0.0%
Forward 5-Year CAGR (Tapered): 0.0%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $58 M
Share Count 5 Years Ago (2020-12-31): $23 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.00
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 10 valid ROE years (max 20).Average ROE: -85.9%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $13.75
52-Week Low: $13.63
Threshold Price (15% Above 52-Week Low): $15.67
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $958 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 12 points to above Pulse Biosciences Inc (PLSE) stock.
Fair Value PE 12, Industry Based PE 18, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 3 values, average assigned is 16.16. The fair value of Pulse Biosciences Inc (PLSE) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
